Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Muhammad Rashad

Pulmonary Disease Charlotte, NC Medical Doctor

NPI 1083843304 CMS profile 3902533

1001 Blythe Blvd, Charlotte, NC 28203

Open in the dashboard

General payments

$14,430

440 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Muhammad Rashad of Charlotte, NC is reported in the CMS Open Payments database as having received $14,430 across 440 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,744 116
2024 General $1,959 85
2023 General $1,919 82
2022 General $5,523 85
2021 General $865 53
2020 General $111 7
2019 General $309 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muhammad Rashad
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Muhammad Rashad were reported at $3,744. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Muhammad Rashad Pulmonary Disease median Middle half National median
2019 $309 $377 $109–$1,340 $163
2020 $111 $230 $56–$907 $114
2021 $865 $269 $68–$1,072 $132
2022 $5,523 $390 $100–$1,457 $149
2023 $1,919 $419 $114–$1,659 $160
2024 $1,959 $476 $123–$1,818 $164
2025 $3,744 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $6,419 34 payments
  2. AstraZeneca Pharmaceuticals LP $1,528 80 payments
  3. GlaxoSmithKline, LLC. $1,042 59 payments
  4. United Therapeutics Corporation $544 20 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $472 21 payments
  6. Mallinckrodt Hospital Products Inc. $464 16 payments
  7. Genzyme Corporation $460 22 payments
  8. Insmed, Inc. $418 21 payments
  9. Regeneron Healthcare Solutions, Inc. $366 17 payments
  10. Amgen Inc. $294 20 payments
  11. Other $2,423 130 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,672 422 payments
  2. Education $4,678 7 payments
  3. Travel and Lodging $1,080 11 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,419 33 payments
  2. ION $3,000 1 payment
  3. TRELEGY ELLIPTA $601 35 payments
  4. TEZSPIRE $505 23 payments
  5. BREZTRI $489 26 payments
  6. ACTHAR $464 16 payments
  7. DUPIXENT $460 22 payments
  8. AIRSUPRA $437 21 payments
  9. Arikayce $385 19 payments
  10. NUCALA $356 19 payments
  11. Other $4,981 257 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,247

Median for Internal Medicine: 777

Drug cost

$1,273,663

Median for Internal Medicine: $73,373

Branded share of claims

72.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 508 $377,565
Ofev Nintedanib Esylate Brand 21 $268,843
Xolair Omalizumab Brand 54 $151,397
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 167 $108,664
Dupixent Pen Dupilumab Brand 29 $106,575
Breo Ellipta Fluticasone/Vilanterol Brand 153 $75,349
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 81 $40,039
Pirfenidone Generic 18 $33,011
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 50 $24,905
Spiriva Respimat Tiotropium Bromide Brand 32 $16,252

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$191,043

Of which drugs: $22,026

Medicare patients

827

Average age 75

Services billed

3,096

450 women, 377 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
COPD 43%
Ischemic heart disease 38%
Diabetes 34%
Heart failure 33%
Atrial fibrillation 33%
Depression 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 27 27 $2,127

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $221
$221 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $116
  • GENZYME CORPORATION $91
$207 29 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $161
$161 508 —
Arikayce
  • Insmed, Inc. $121
$121 — —
TYVASO
  • United Therapeutics Corporation $117
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record